Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.
J Am Coll Cardiol. 2018.
PMID: 29540325
Free article.
Clinical Trial.
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M; CVD-REAL Investigators and Study Group.
Cavender MA, et al.
J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085.
J Am Coll Cardiol. 2018.
PMID: 29852973
Free article.
Item in Clipboard
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Wittbrodt E, Hammar N, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group.
Thuresson M, et al.
Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338.
Diabetes Care. 2018.
PMID: 29784708
No abstract available.
Item in Clipboard
Cite
Cite